100 jobs to go and two research labs to close following fall-out from budget.

Sydney biomedical company Sirtex Medical (ASX:SRX) has posted a positive net cash flow for the second quarter of 2005/06 of AUD$1.46 million, an increase of 87 per cent on the previous quarter.

Researchers at Melbourne's Peter MacCallum Cancer Centre have begun testing a high-precision, antibody-mediated system to deliver short-range radionuclides to cancerous cells.

The Australian Synchrotron project has scored another AUD$5 million funding for the initial suite of beamlines from the Australian Nuclear Science and Technology Organisation (ANSTO), which joins the University of Melbourne, Monash University, CSIRO and MiniFAB as a foundation partner.

Sydney biomedical company Sirtex Medical Ltd (ASX:SRX) has announced it has purchased a US manufacturing site in Wilmington, Massachusetts, at a cost of US$990,000, funded though a mortgage over the property.

Sirtex Medical has reported an increase in revenues of 1368 per cent, recording more than AUD$10 million in revenues for the 12 months ending June 30, and an after-tax profit of $3.15 million.

The new nuclear reactor at Lucas Heights, in Sydney, will give Australian medical researchers access to the latest therapeutic radioisotopes, according to the head of the facility's radioisotope manufacturing arm.